A sea anemone has revealed a way of fighting viruses that runs in the opposite direction to the one in human cells, a peptide from a deep-sea sponge off a Japanese island has been shown to attack cancer cells through two separate mechanisms at once, and pharmaceutical regulators on two continents have formally endorsed a lab-grown replacement for one of medicine’s strangest quality-control ingredients: the blue blood of the horseshoe crab. None of these findings came from a hospital or a conventional laboratory model species. They came from the ocean, which in 2026 is proving to be as productive a source of biomedical insight as any land-based research programme.

Marine organisms have spent more than 600 million years solving biological problems, immune defence, chemical warfare, molecular signalling, in isolation from the terrestrial lineage that produced humans, mice and the handful of other species most biomedical research is built around. That isolation is exactly what makes the ocean useful now. Three findings from this year show what happens when researchers go looking for answers somewhere evolution has never been asked the same questions before.

A Sea Anemone Fights Viruses Backwards

In June, a team led by PhD candidate Ton Sharoni and Professor Yehu Moran at the Hebrew University of Jerusalem, working with collaborators at the University of North Carolina at Charlotte, published a discovery in Nature Ecology & Evolution that upends a basic assumption about how animal immune systems evolved. In humans and other vertebrates, a protein called MAVS detects viral invaders and switches on the body’s antiviral defences. The researchers found a strikingly similar protein in the sea anemone Nematostella vectensis, which they named CARDIB, and assumed it would work the same way. It does the opposite. Rather than activating antiviral genes, CARDIB normally suppresses them, and when the researchers used CRISPR gene editing to delete it from sea anemones and exposed the animals to viruses, in both laboratory tanks and outdoor marine mesocosms in South Carolina, the CARDIB-free anemones became markedly more vulnerable to infection. The suppressor, it turned out, is essential to mounting an effective defence. “Humans and sea anemones both need protection from viruses,” said Moran, “but this work shows that evolution can organise those defences in fundamentally different ways.” The finding matters beyond marine biology: it shows that the antiviral toolkit found in humans is not the only viable design, which is exactly the kind of alternative blueprint drug developers look for when a human pathway proves difficult to target directly.

A Deep-Sea Sponge Compound That Attacks Cancer Two Ways at Once

The second finding concerns a much older marine discovery that has just revealed a second trick. Yaku’amide B is a structurally complex compound isolated from a deep-sea sponge found off Yakushima Island in Japan, and it was already known to kill cancer cells by lodging in their mitochondria and shutting down ATP synthase, the enzyme that generates cellular energy. In January, a team led by Professor Kaori Sakurai at the Tokyo University of Agriculture and Technology, working with colleagues at the University of Tokyo, published new findings in the Journal of the American Chemical Society showing the compound has a second, entirely separate mode of attack. Using a specially designed probe, the researchers found that yaku’amide B also binds transiently to CD9, a protein on the surface of cancer stem cells that marks out the aggressive, treatment-resistant cells most responsible for recurrence and metastasis, and triggers its degradation inside the cell. Yaku’amide B is the first natural product ever reported to induce CD9 degradation. A compound that can starve a cancer cell of energy and dismantle one of its key resistance markers at the same time, using two unrelated mechanisms, is a rare enough combination that it justifies the decades marine natural product chemists have spent hauling sediment and sponge samples up from the ocean floor in search of exactly this kind of molecule.

Retiring the Horseshoe Crab From the Drug Testing Line

The third development is not a new discovery so much as the arrival of one at regulatory maturity. For decades, every batch of injectable medicine, vaccine and implanted medical device manufactured anywhere in the world has had to be tested for bacterial endotoxins, using a reagent called Limulus Amebocyte Lysate, drawn from the blue, copper-based blood of horseshoe crabs harvested from wild populations. A synthetic alternative, recombinant Factor C, has existed since the 1990s, but for years it sat in a regulatory grey zone as an “alternative” method rather than an accepted equal. That changed on both sides of the Atlantic in quick succession. In May 2025, the United States Pharmacopeia formally introduced Chapter 86, putting recombinant reagent-based endotoxin tests on the same official footing as the traditional crab-blood test for the first time. Then, on 23 July 2026, Brazil’s National Council for the Control of Animal Experimentation went further, publishing Resolution No. 77/2026, which recognises recombinant Factor C as the official, preferred method for endotoxin detection in Brazil and sets a five-year transition period for it to formally replace the horseshoe crab-derived test, except where a manufacturer can demonstrate a specific product incompatibility. It is a slower, more bureaucratic story than a new molecule or a reprogrammed immune pathway, but it is arguably the most consequential of the three: a change to how essentially every sterile drug on the planet gets tested, driven by conservation pressure on a wild marine species whose blood the pharmaceutical industry has relied on since the 1970s.

The Ocean as an Unfinished Reference Library

What connects a sea anemone’s inverted immune circuit, a sponge compound with a double mechanism, and a regulatory chapter retiring a horseshoe crab blood test is the same underlying fact: the ocean has been running its own biological experiments for longer, and more independently, than land ever has, and very little of what it has produced has been catalogued. Marine invertebrates alone are estimated to produce more antibiotic, anticancer and anti-inflammatory compounds than any comparable group of land organisms, and researchers studying deep-sea natural products have repeatedly found the ocean floor undersampled relative to its chemical diversity. Each of this year’s findings, an immune mechanism nobody expected, a two-pronged cancer compound decades after its first discovery, a manufacturing standard finally catching up with a species under conservation pressure, is a reminder that the sea is not a finished reference book life sciences has already read. It is one still being opened.

Sources include Nature Ecology & Evolution, the Hebrew University of Jerusalem, the Journal of the American Chemical Society, the Tokyo University of Agriculture and Technology, the United States Pharmacopeia, and Humane World for Animals.